Status:
UNKNOWN
Sufentanil Intranasal
Lead Sponsor:
Centre Hospitalier Universitaire Saint Pierre
Conditions:
Emergencies
Pain, Acute
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Study of the effects of intranasal sufentanil on patients presenting to the emergency department with acute post-traumatic pain.
Detailed Description
In this study, patients presenting to the emergency department with post-traumatic pain of 7 or more on the visual analog pain scale, since less than 24 hours, in the limbs, spine or thorax are random...
Eligibility Criteria
Inclusion
- posttraumatic pain + lasting for less than 24 hours + with an analog visual pain scale of 7/10 or more
Exclusion
- pregnant
- \<18 years
- prisoners
- lesions of head, face or abdomen
- no consent given or possible
- pain not scorable
- known drug abuse or substitution therapy
- chronic level 3 pain medication
- intake of level 3 \< 8 hours
- intoxicated patient
- allergy or intolerance to opiates
- renal or hepatic insufficiency
- \< 50kg body weight
- hemodynamic instability
Key Trial Info
Start Date :
January 22 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT04137198
Start Date
January 22 2020
End Date
September 1 2025
Last Update
February 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Saint Pierre
Brussels, Belgium, 1000